IL123290A - Iontophoretic device - Google Patents
Iontophoretic deviceInfo
- Publication number
- IL123290A IL123290A IL12329098A IL12329098A IL123290A IL 123290 A IL123290 A IL 123290A IL 12329098 A IL12329098 A IL 12329098A IL 12329098 A IL12329098 A IL 12329098A IL 123290 A IL123290 A IL 123290A
- Authority
- IL
- Israel
- Prior art keywords
- eye
- hydrogel
- carrier
- drug
- receiving portion
- Prior art date
Links
- 239000003814 drug Substances 0.000 claims abstract description 61
- 229940079593 drug Drugs 0.000 claims abstract description 60
- 239000000017 hydrogel Substances 0.000 claims abstract description 48
- 239000000499 gel Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- -1 crosslinked Substances 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 229920003020 cross-linked polyethylene Polymers 0.000 claims description 2
- 239000004703 cross-linked polyethylene Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000001508 eye Anatomy 0.000 description 46
- 229930182566 Gentamicin Natural products 0.000 description 30
- 229960002518 gentamicin Drugs 0.000 description 30
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 29
- 239000000243 solution Substances 0.000 description 20
- 210000004087 cornea Anatomy 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 7
- 229920000189 Arabinogalactan Polymers 0.000 description 7
- 239000001904 Arabinogalactan Substances 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 235000019312 arabinogalactan Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000008272 agar Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102100026735 Coagulation factor VIII Human genes 0.000 description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 4
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 4
- 229960000707 tobramycin Drugs 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000005357 flat glass Substances 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- QLIBJPGWWSHWBF-UHFFFAOYSA-N 2-aminoethyl methacrylate Chemical class CC(=C)C(=O)OCCN QLIBJPGWWSHWBF-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical class C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910004882 Na2S2O8 Inorganic materials 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 201000005228 cornea cancer Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- MSYFVTLZGPOXGM-UHFFFAOYSA-N octa-2,6-dienediamide Chemical compound NC(=O)C=CCCC=CC(N)=O MSYFVTLZGPOXGM-UHFFFAOYSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12329098A IL123290A (en) | 1998-02-13 | 1998-02-13 | Iontophoretic device |
| DK99903888T DK1054705T3 (da) | 1998-02-13 | 1999-02-05 | Anordning til iontoforetisk indgivelse af lægemidler |
| EP99903888A EP1054705B1 (en) | 1998-02-13 | 1999-02-05 | A device for iontophoretic administration of drugs |
| US09/622,097 US6442423B1 (en) | 1998-02-13 | 1999-02-05 | Device for iontophoretic administration of drugs |
| ES99903888T ES2233019T3 (es) | 1998-02-13 | 1999-02-05 | Dispositivo para la administracion iontoforetica de farmacos. |
| DE69921779T DE69921779T2 (de) | 1998-02-13 | 1999-02-05 | Vorrichtung zur iontophoretischen verabreichung von medikamenten |
| PCT/IL1999/000077 WO1999040967A1 (en) | 1998-02-13 | 1999-02-05 | A device for iontophoretic administration of drugs |
| AU24389/99A AU2438999A (en) | 1998-02-13 | 1999-02-05 | A device for iontophoretic administration of drugs |
| AT99903888T ATE281871T1 (de) | 1998-02-13 | 1999-02-05 | Vorrichtung zur iontophoretischen verabreichung von medikamenten |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12329098A IL123290A (en) | 1998-02-13 | 1998-02-13 | Iontophoretic device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL123290A0 IL123290A0 (en) | 1998-09-24 |
| IL123290A true IL123290A (en) | 2001-12-23 |
Family
ID=11071234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12329098A IL123290A (en) | 1998-02-13 | 1998-02-13 | Iontophoretic device |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6442423B1 (es) |
| EP (1) | EP1054705B1 (es) |
| AT (1) | ATE281871T1 (es) |
| AU (1) | AU2438999A (es) |
| DE (1) | DE69921779T2 (es) |
| DK (1) | DK1054705T3 (es) |
| ES (1) | ES2233019T3 (es) |
| IL (1) | IL123290A (es) |
| WO (1) | WO1999040967A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7346389B1 (en) * | 1998-09-24 | 2008-03-18 | Newsome David A | Dilation enhancer with pre-medicated contact lenses |
| US6319240B1 (en) * | 1999-05-25 | 2001-11-20 | Iomed, Inc. | Methods and apparatus for ocular iontophoresis |
| US7252655B2 (en) | 1999-05-25 | 2007-08-07 | Iomed, Inc. | Ocular iontophoretic apparatus handle |
| US6728573B1 (en) | 2000-02-23 | 2004-04-27 | Iomed, Inc. | Ocular iontophoretic apparatus handle |
| US6539251B2 (en) | 1999-05-25 | 2003-03-25 | Iomed, Inc. | Ocular iontophoretic apparatus |
| US6546283B1 (en) * | 2000-10-18 | 2003-04-08 | Iomed, Inc. | High current density iontophoretic device and method of use thereof |
| US20030023228A1 (en) * | 2001-07-20 | 2003-01-30 | Parkinson Thomas M. | Ocular iontophoretic device and method for using the same |
| WO2003007798A2 (en) * | 2001-07-20 | 2003-01-30 | Iomed, Inc. | Ophthalmic use of 5 fluorourcil |
| FR2830766B1 (fr) * | 2001-10-12 | 2004-03-12 | Optis France Sa | Dispositif de delivrance de medicaments par iontophorese transpalpebrale |
| WO2004073794A2 (en) * | 2003-02-19 | 2004-09-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Device, methods and sponges for iontophoretic drug delivery |
| EP1624938B1 (en) | 2003-05-20 | 2011-03-16 | James F. Collins | Ophthalmic drug delivery system |
| US8012136B2 (en) | 2003-05-20 | 2011-09-06 | Optimyst Systems, Inc. | Ophthalmic fluid delivery device and method of operation |
| FR2855761B1 (fr) * | 2003-06-03 | 2006-02-24 | Optis France Sa | Dispositif oculaire de delivrance variable de principes actifs par iontophorese |
| WO2005084748A1 (en) | 2004-03-04 | 2005-09-15 | Hadasit Medical Research Services & Development Company Ltd. | Safe device for iontophoretic delivery of drugs |
| US20060089590A1 (en) * | 2004-10-27 | 2006-04-27 | John Higuchi | Methods and devices for sustained in-vivo release of an active agent |
| WO2006072887A1 (en) | 2005-01-05 | 2006-07-13 | Eyegate Pharma Sa | Ocular iontophoresis device for delivering sirna and aptamers |
| US20080233053A1 (en) * | 2005-02-07 | 2008-09-25 | Pharmalight Inc. | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients |
| US20070260171A1 (en) * | 2005-09-27 | 2007-11-08 | Higuchi John W | Intraocular iontophoretic device and associated methods |
| US8755880B2 (en) * | 2005-10-24 | 2014-06-17 | Aciont, Inc. | Intraocular iontophoretic device and associated methods |
| US8634907B2 (en) * | 2005-10-24 | 2014-01-21 | Aciont, Inc. | Intraocular iontophoretic device and associated methods |
| US8099162B2 (en) * | 2005-11-29 | 2012-01-17 | Eyegate Pharma, S.A.S. | Ocular iontophoresis device |
| KR20130051476A (ko) | 2010-07-15 | 2013-05-20 | 코린시언 아프샐믹 인코포레이티드 | 안과용 약물 전달 |
| CA2805635A1 (en) | 2010-07-15 | 2012-01-19 | Corinthian Ophthalmic, Inc. | Method and system for performing remote treatment and monitoring |
| CA2805426C (en) | 2010-07-15 | 2020-03-24 | Corinthian Ophthalmic, Inc. | Drop generating device |
| US10154923B2 (en) | 2010-07-15 | 2018-12-18 | Eyenovia, Inc. | Drop generating device |
| PT2648663E (pt) | 2011-01-12 | 2015-07-29 | Sooft Italia S P A | Dispositivo para administração por iontoforese de riboflavina na córnea para o tratamento de queratocone |
| US20130172830A1 (en) | 2011-12-12 | 2013-07-04 | Corinthian Ophthalmic, Inc. | Ejector mechanism, ejector device, and methods of use |
| US11938056B2 (en) | 2017-06-10 | 2024-03-26 | Eyenovia, Inc. | Methods and devices for handling a fluid and delivering the fluid to the eye |
| CA3164288A1 (en) | 2019-12-11 | 2021-06-17 | Eyenovia, Inc. | Systems and devices for delivering fluids to the eye and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61279257A (ja) * | 1985-06-05 | 1986-12-10 | 林原 健 | 眉毛発育装置 |
| US5250022A (en) | 1990-09-25 | 1993-10-05 | Rutgers, The State University Of New Jersey | Iontotherapeutic devices, reservoir electrode devices therefore, process and unit dose |
| US5160316A (en) * | 1990-09-10 | 1992-11-03 | Henley Julian L | Iontophoretic drug delivery apparatus |
| US7027859B1 (en) * | 1994-09-26 | 2006-04-11 | Alza Corporation | Electrotransport delivery device having improved safety and reduced abuse potential |
| AUPM982694A0 (en) * | 1994-12-02 | 1995-01-05 | University Of Queensland, The | Iontophoresis method and apparatus |
| US5676648A (en) | 1996-05-08 | 1997-10-14 | The Aps Organization, Llp | Iontophoretic drug delivery apparatus and method for use |
| US6101411A (en) * | 1998-09-24 | 2000-08-08 | Newsome; David A. | Dilation enhancer |
| US6319240B1 (en) * | 1999-05-25 | 2001-11-20 | Iomed, Inc. | Methods and apparatus for ocular iontophoresis |
-
1998
- 1998-02-13 IL IL12329098A patent/IL123290A/en not_active IP Right Cessation
-
1999
- 1999-02-05 ES ES99903888T patent/ES2233019T3/es not_active Expired - Lifetime
- 1999-02-05 AT AT99903888T patent/ATE281871T1/de not_active IP Right Cessation
- 1999-02-05 EP EP99903888A patent/EP1054705B1/en not_active Expired - Lifetime
- 1999-02-05 AU AU24389/99A patent/AU2438999A/en not_active Abandoned
- 1999-02-05 WO PCT/IL1999/000077 patent/WO1999040967A1/en not_active Ceased
- 1999-02-05 DK DK99903888T patent/DK1054705T3/da active
- 1999-02-05 DE DE69921779T patent/DE69921779T2/de not_active Expired - Lifetime
- 1999-02-05 US US09/622,097 patent/US6442423B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69921779D1 (de) | 2004-12-16 |
| EP1054705B1 (en) | 2004-11-10 |
| DE69921779T2 (de) | 2005-12-15 |
| WO1999040967A1 (en) | 1999-08-19 |
| AU2438999A (en) | 1999-08-30 |
| EP1054705A1 (en) | 2000-11-29 |
| ES2233019T3 (es) | 2005-06-01 |
| IL123290A0 (en) | 1998-09-24 |
| US6442423B1 (en) | 2002-08-27 |
| ATE281871T1 (de) | 2004-11-15 |
| DK1054705T3 (da) | 2005-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1054705B1 (en) | A device for iontophoretic administration of drugs | |
| JP4308353B2 (ja) | イオン滲透療法による活性物質の眼内移入装置 | |
| US20200139098A1 (en) | Delivery system and process | |
| JPH09503412A (ja) | イオン導入促進デリバリーのための使い捨て式投与ユニット | |
| US9555238B2 (en) | Safe device for iontophoretic delivery of drugs | |
| US20080139990A1 (en) | Presbyopia Treatment by Lens Alteration | |
| Eljarrat-Binstock et al. | Hydrogel probe for iontophoresis drug delivery to the eye | |
| US8290579B2 (en) | Device, methods and sponges for iontophoretic drug delivery | |
| JP2004533861A (ja) | 眼用イオン導入装置およびそれを用いる血管内皮細胞増殖因子（ｖｅｇｆ）の阻害方法 | |
| Frucht-Pery et al. | Iontophoresis–gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe | |
| JP5913606B2 (ja) | 円錐角膜の治療に有効であり、イオントフォレシスにより導入される改良された架橋結合組成物 | |
| JP3959119B2 (ja) | 放出可能な薬物を含む眼内レンズ | |
| AU2017203326A1 (en) | A delivery system and process | |
| AU2007260594B2 (en) | A delivery system and process | |
| FRUCHT-PERY et al. | Hydrogel probe for iontophoresis drug delivery to the eye | |
| Eljarrat-Binstock et al. | Hydrogel iontophoresis for gentamicin administration to the rabbit eye | |
| HK1134047B (en) | A delivery system and process | |
| JP2004535462A (ja) | 眼、眼球結膜、眼瞼結膜、瞼、眼窩周囲の軟組織及び皮膚の細胞増殖阻害剤として、イオン導入によって送達する５−フルオロウラシルの使用方法。 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |